• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

    5.260 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 56
    Open 5.260
    Bid (Size) 5.000 (500)
    Ask (Size) 5.390 (1,100)
    Prev. Close 5.260
    Today's Range 5.260 - 5.260
    52wk Range 4.250 - 14.60
    Shares Outstanding 28,919,810
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
    Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
    From Candel Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -41.5%
    -41.5%
    1 Month
    +2.5%
    +2.5%
    3 Month
    +7.5%
    +7.5%
    6 Month
    -5.2%
    -5.2%
    1 Year
    +18.7%
    +18.7%

    More News

    Read More
    News headline image
    Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗
    Via Stocktwits
    News headline image
    Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗
    Via Benzinga
    News headline image
    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at the SITC 2025 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Participate in Upcoming Investor Conferences in September
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Reports 88 Percent Q2 Loss Drop ↗
    Via The Motley Fool
    News headline image
    Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
    From Candel Therapeutics
    Via GlobeNewswire
    News headline image
    Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
    From Candel Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Candel Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
    Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
    The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
    What is the current price of Candel Therapeutics, Inc. - Common Stock?
    The current price of Candel Therapeutics, Inc. - Common Stock is 5.260
    When was Candel Therapeutics, Inc. - Common Stock last traded?
    The last trade of Candel Therapeutics, Inc. - Common Stock was at 12/04/25 04:00 PM ET
    What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?
    The market capitalization of Candel Therapeutics, Inc. - Common Stock is 152.12M
    How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?
    Candel Therapeutics, Inc. - Common Stock has 152M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.